Pharmacokinetics Distribution of Raltegravir by PET/MR
Part of paid clinical trials in San Francisco, California.
- Sponsor
- University of California, San Francisco
- Study ID
- NCT03174977
- Phase
- EARLY_PHASE1
- Status
- Recruiting
Conditions
- HIV-1-infection
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- 18F-Raltegravir — DRUGA single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
Study Details
This is a single-center drug distribution and pharmacokinetic study of a single microdose of 18F-raltegravir given to 10 HIV-infected subjects who are either taking or not taking a raltegravir-containing ART regimen. After administration of IV 18F-raltegravir, subjects will undergo PET/MRI in order to determine the distribution of radiolabeled drug through the lymphoreticular system and other tissues throughout the entire body.
Key Dates
- Start date
- Apr 1, 2018
- Status verified
- Jun 2024
- Primary completion
- Nov 1, 2024
- Completion
- Jan 1, 2025
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: 18F-Raltegravir
Primary Outcome Measure
Number of patients with microdose (<2.5 millicurie; mCi) 18F-Raltegravir-related adverse events as measured by clinical observation during single intravenous dose administration and PET/MR imaging [ Time Frame: One imaging session within 1 to 6 hours following administration of 18F-Raltegravir ]
Central Contacts
- Timothy J Henrich, MD415-206-5518
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94110 | Timothy J Henrich, MD (PRINCIPAL_INVESTIGATOR) Henry F Vanbrocklin, PhD (SUB_INVESTIGATOR) Steven J Deeks, MD (SUB_INVESTIGATOR) Benajamin Franc, MD (SUB_INVESTIGATOR) Francesca Aweeka, PharmD (SUB_INVESTIGATOR) |
Find similar trials in San Francisco, CA
Related Studies
- PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)PHASE1 · Recruiting · University of California, San Francisco · San Francisco, California
- Cannabis Use, Cognition, and the Endocannabinoid System in HIVEARLY_PHASE1 · Recruiting · University of California, San Diego · San Diego, California
- Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101PHASE1 · Enrolling By Invitation · Excision BioTherapeutics · San Francisco, California
- Observational PIC Destination CohortRecruiting · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · San Francisco, California